Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 289

Sort by

Sort Order Select

Journal Articles

Real-World Patterns of MRD Testing and Impact on Treatment for Chronic Lymphocytic Leukemia Patients

Melissa Bacchus, MHS, PA-C, Nivita Singh-Bulkan, Hana E. Littleford, Joseph Kim, Richard L. Martin, Alix M.B. Lacoste, Elise Brimble, Conner O'Brien, Larry A. Saltzman, Lee M. Greenberger, Amanda Nottke

Blood (2023) 142 (Supplement 1): 6527.

https://doi.org/10.1182/blood-2023-174944

Published: 2023

Journal Articles

A Patient-Centric Registry Dataset Generates Real-World Insights about Cause, Timing, Type, and Impact of Cardiotoxic Adverse Events in Chronic Lymphocytic Leukemia

Hana E. Littleford, Nivita Singh-Bulkan, Melissa Bacchus, MHS, PA-C, Joseph Kim, Richard L. Martin, Alix M.B. Lacoste, Elise Brimble, Conner O'Brien, Larry A. Saltzman, Lee M. Greenberger, Amanda Nottke

Blood (2023) 142 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2023-177734

Published: 2023

Journal Articles

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

Radovan Vasic, MD MHS, Yuliang Shi, Andrea Arruda, MSc, Sarah Malik, Jaime Claudio, PhD, Jose-Mario Capo-Chichi, PhD, Aniket Bankar, MBBS, MD DM, Hassan Sibai, MBBS, Dawn Maze, MDFRCPC,MSc, James A. Kennedy, MDPhD, Wei Xu, PhD, Vikas Gupta, MD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-139936

Published: 2020

Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137734

Published: 2020

Journal Articles

Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

Joshua F. Zeidner, MD, Flora Mazerolle, MSc, Jill A. Bell, PhD MS, Lauren E. Cain, MHS, ScM, PhD, Douglas V. Faller, Mehul Dalal, PhD, Antoine Regnault, PhD, Robert J. Fram

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136935

Published: 2020

Journal Articles

A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL)

Omer M Ali, MD, Sahil S Nalawade, MS, Yin Xi, PhD, Ben Wagner, BM, Alexander Mazal, MD, Shane Ahlers, MD, Syed M Rizvi, MD, Farrukh T Awan, MD, Kiran A Kumar, MD MBA, Neil B Desai, MD MHS, Joseph A Maldjian, MD, Marco C Pinho, MD, Praveen Ramakrishnan Geethakumari, MD MS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141941

Published: 2020

Journal Articles

Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study

Suleyman Y Goksu, MD, Jude Khatib, MD, Busra N Bacik Goksu, Rong Wang, PhD, Prapti A. Patel, MD, Madhuri Vusirkala, MD, Suzanne Cole, MD, Ahmet Seyhanli, MD, Muhammet Ozer, MD, Robert H. Collins, MD, Stephen Chung, MD, Amer M. Zeidan, MBBS, MHS, Yazan F. Madanat, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140564

Published: 2020

Journal Articles

Functional Assessment in Younger and Older Adults with Sickle Cell Disease

Charity I Oyedeji, MD, Carl Pieper, PhD, Katherine Hall, PhD, Miriam Morey, PhD, Heather Whitson, MD MHS, John J. Strouse, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140854

Published: 2020

Journal Articles

Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System

Akshat M Patel, Omer M Ali, MD, Radhika Kainthla, MD, Syed M Rizvi, MD, Farrukh T Awan, MD, Neil B Desai, MD MHS, Robert Timmerman, MD, Kiran A Kumar, MD MBA, Praveen Ramakrishnan Geethakumari, MD MS

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138568

Published: 2020

Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139752

Published: 2020

Journal Articles

Hydroxyurea Is a Potential Risk Factor for Diminished Ovarian Reserve in Young Adults with Sickle Cell Anemia

Lydia H. Pecker, MD, Sarah Hussain, Jaanvi Mahesh, Ravi Varadhan, PhD, Mindy S Christianson, MD MBA, Sophie M. Lanzkron, MD MHS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136011

Published: 2020

Journal Articles

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134730

Published: 2020

Journal Articles

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Hongbo Yang, PhD, Andy Garnham, MSc, Manasee V. Shah, MPH, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-136184

Published: 2020

Journal Articles

Incidence of Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium

Julie Jaffray, MD, Lisa Baumann Kreuziger, MD MS, Brian Branchford, MD, Arash Mahajerin, Choo Phei A Wee, E Vince S Faustino, MD MHS, Zakai A Neil, MD, Stacy E. Croteau, MD, Michael Silvey, DO, John Fargo, DO, James D. Cooper, MD, Nihal Bakeer, MD, Amy Stillings, Emily Krava, Guy Young, MD, Neil A Goldenberg, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137216

Published: 2020

Journal Articles

Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Rong Wang, PhD, Rory M. Shallis, MD, Jan Philipp Bewersdorf, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139468

Published: 2020

Journal Articles

Young Adults with Sickle Cell Disease (SCD) Have Low Interest in Genetic Counseling and Sickle Cell Trait Testing for Sexual Partners

Elizabeth Williams, BA, Elizabeth Linton, MPH, Rosalyn Stewart, MBA., MD MS, Sophie M. Lanzkron, MD MHS, Lydia H. Pecker, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140867

Published: 2020

Journal Articles

Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis

Jan Philipp Bewersdorf, MD, Martin S. Tallman, MD, Christina Cho, MD, Amer M. Zeidan, MBBS, MHS, Maximilian Stahl, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-136671

Published: 2020

Journal Articles

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Amy J. Davidoff, PhD, Jessica B Long, MPH, Natalia Neparidze, MD, Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Rong Wang, PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140728

Published: 2020

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-139428

Published: 2020

NARROW

Real-World Patterns of MRD Testing and Impact on Treatment for Chronic Lymphocytic Leukemia Patients

A Patient-Centric Registry Dataset Generates Real-World Insights about Cause, Timing, Type, and Impact of Cardiotoxic Adverse Events in Chronic Lymphocytic Leukemia

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL)

Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study

Functional Assessment in Younger and Older Adults with Sickle Cell Disease

Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System

Hydroxyurea Is a Potential Risk Factor for Diminished Ovarian Reserve in Young Adults with Sickle Cell Anemia

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Incidence of Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium

Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Young Adults with Sickle Cell Disease (SCD) Have Low Interest in Genetic Counseling and Sickle Cell Trait Testing for Sexual Partners

Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only